Risks

High leverage and thin interest coverage increase refinancing sensitivity, leaving ESPR more exposed than larger specialty peers with stronger balance sheets and lower funding risk.

A long cash conversion cycle driven by elevated receivables and inventory ties up working capital, limiting flexibility versus peers with faster cash generation and leaner operations.

Current and quick ratios above 1.0 provide near-term liquidity, but they remain modest relative to better-capitalized peers, constraining shock absorption if demand softens.

Negative equity and elevated net debt to EBITDA signal a fragile capital structure, which can amplify downside if execution or market access deteriorates versus peers.

Limited free-cash-flow visibility reduces the buffer to absorb operating volatility, making ESPR less resilient than peers with recurring cash generation and stronger self-funding capacity.

Opportunities

Liquidity ratios above 1.0 suggest ESPR can fund near-term operations, giving it more runway than distressed peers that face immediate financing pressure.

If working capital normalizes, the very long cash conversion cycle could release cash and improve flexibility faster than peers already operating near efficient levels.

Specialty-pharma positioning can support differentiated demand versus broader generic peers, but the upside depends on sustained product uptake and pricing discipline.

High leverage can magnify equity upside if operating performance improves, yet this benefit is less reliable than for peers with cleaner balance sheets and lower dilution risk.

Overall Score

ESPR’s forward positioning is constrained by leverage, weak coverage, and working-capital intensity, while near-term liquidity and potential cash release provide only moderate upside versus peers.